US FDA’s Woodcock Sees Clinical Trial Reform Coming, But ‘Not Wholly Optimistic’

 
• By Derrick Gingery

Acting FDA commissioner says there are a lot of strong forces in the research and pharma industries that could curb efforts to make pandemic-related clinical trial reforms permanent.

Margaret Hamburg (left) and Janet Woodcock (right)
Former Commissioner Margaret Hamburg and Acting Commissioner Janet Woodcock reminisce about the duties of the job during the Milken Institute Partnering for Patients Forum. • Source: Screenshot from Milken Institute Partnering for Patients Forum

More from Clinical Trials

More from R&D